Biodistribution of AGuIX Nanoparticles in Brain Metastases via MRI in NANORAD2 Trial

Overview

This study quantitatively assessed the biodistribution and kinetics of AGuIX gadolinium-based theranostic nanoparticles in patients with multiple brain metastases undergoing whole-brain radiotherapy (WBRT). MRI evaluations at 1 and 4 hours post-injection and after three weekly doses demonstrated preferential accumulation in brain metastases with limited retention in healthy brain and adjacent organs.

Background

Radiotherapy is essential in cancer treatment but is limited by toxicity to radiosensitive tissues, especially in brain metastases. Radiosensitizers like metallic nanoparticles can enhance tumor response by increasing local dose deposition. AGuIX nanoparticles, gadolinium-based and approximately 5 nm in size, serve as both radiosensitizers and MRI contrast agents, enabling non-invasive monitoring of their distribution. The NANORAD2 phase II trial investigates the safety and efficacy of AGuIX combined with WBRT in patients with multiple brain metastases.

Data Highlights

Key Findings

• AGuIX nanoparticles preferentially accumulate in brain metastases compared to healthy brain tissue, as shown by enhanced T1-weighted MRI contrast.
• Early kinetic analysis between 1 and 4 hours post-injection indicates partial clearance of nanoparticles from non-target regions while retention persists in metastases.
• Repeated weekly injections over two weeks do not lead to significant off-target accumulation in healthy brain or adjacent organs.
• The small size (~5 nm) of AGuIX facilitates tumor interstitial and cellular penetration via the enhanced permeability and retention (EPR) effect.
• AGuIX’s gadolinium core enables simultaneous radiosensitization and MRI-based theranostic monitoring.

Clinical Implications

The preferential and sustained accumulation of AGuIX in brain metastases supports its use as a radiosensitizer to enhance the efficacy of WBRT while minimizing toxicity to healthy brain tissue. MRI monitoring of nanoparticle distribution can guide optimal timing of radiotherapy to maximize tumor radiosensitization. The lack of significant off-target retention after repeated dosing suggests a favorable safety profile for clinical use.

Conclusion

This ancillary study of the NANORAD2 trial demonstrates that AGuIX nanoparticles selectively accumulate in brain metastases with favorable pharmacokinetics, supporting their potential to improve radiotherapy outcomes through combined imaging and radiosensitization. These findings inform optimal scheduling and safety considerations for integrating AGuIX into clinical protocols.

References

1. Le Duc et al. 2024 -- Biodistribution of AGuIX Theranostic Nanoparticles Assessed by MRI in NANORAD2 Clinical Trial